Trial Profile
A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Sep 2019
Price :
$35
*
At a glance
- Drugs IAB 2M (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors ImaginAb Inc
- 02 Aug 2016 Status changed from active, no longer recruiting to completed.
- 06 Jan 2016 According to an ImaginAb media release, the results will be presented at the Genitourinary (GU) Cancers Symposium 2016.
- 06 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to the results published in an ImaginAb media release.